Enanta Pharmaceuticals joins the hunt for coronavirus treatments

Enanta Pharmaceuticals CEO Jay Luly
Enanta will launch a discovery program to seek out new drugs to treat COVID-19, and it will plumb its library of antiviral compounds for candidates that show promise against the disease. (Enanta Pharmaceuticals)

The hunt is on for a treatment against COVID-19, the disease caused by the novel coronavirus circulating the globe. Some players, like Sanofi and Regeneron, are repurposing older drugs, while others are developing brand-new treatments. Liver specialist Enanta Pharmaceuticals is joining the latter camp.

Enanta will launch a discovery program to seek out new drugs to treat COVID-19, and it will plumb its library of antiviral compounds for candidates that show promise against the disease, the company said in a statement.

“Based on our proven track record in virology and our capabilities in respiratory diseases, we believe our core competencies position us well to discover a potential treatment for COVID-19,” said Enanta CEO Jay Luly, Ph.D., in the statement. “Our decision to initiate a program for COVID-19 is a natural evolution of our work and mission.”

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Thwarting coronaviruses by preventing them from copying themselves

The Massachusetts-based biotech partnered with AbbVie on two antivirals that eventually became part of the Big Pharma’s hepatitis C treatments Viekira Pak and its follow-up Mavyret. Enanta’s pipeline includes programs in multiple liver diseases: hepatitis B, nonalcoholic steatohepatitis and primary biliary cholangitis. It’s also working on treatments against the respiratory syncytial virus and human metapneumovirus.

RELATED: Chinese firm copies Gilead's remdesivir, the most promising drug against the new coronavirus

Enanta joins a group of biotech companies working on new treatments for COVID-19 including Vir Biotechnology, which identified two monoclonal antibodies that bind to the novel coronavirus, SARS-CoV-2. The company is digging into the ability of those antibodies—or other antibodies—to ward off or treat COVID-19. Takeda and Israel-based Kamada are both working on treatments based on plasma from patients who have recovered from the disease.

AbbVie is working with health authorities to test its HIV medicine Kaletra/Aluvia in patients who have contracted the coronavirus, while Sanofi and Regeneron are preparing to pit rheumatoid arthritis med Kevzara against COVID-19. And Gilead’s remdesivir, which fell short against Ebola, is showing promise against the coronavirus, with a Chinese firm mass-producing copies of the antiviral.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.